Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
IRCCS San Raffaele
100 participants
Apr 30, 2023
OBSERVATIONAL
Conditions
Summary
Prospective observational clinical, molecular, translational study aimed at identifying the main determinants and predictive factors of fragility fracture risck in acromegaly patients
Eligibility
Inclusion Criteria3
- confirmed diagnosis of acromegaly
- availability to carry out outpatient checks
- ability to provide informed consent
Exclusion Criteria9
- Pregnancy
- use of glucocorticoids (except those in use for replacement therapy)
- alcohol abuse
- exacerbation of chronic disease
- serious comorbidities (renal or hepatic failure, heart attack, stroke)
- terminally ill, prolonged immobilization (>1 week)
- clinically evident fracture within the previous six months
- any other cause of secondary osteoporosis within the last five years
- any prolonged treatment with drugs with documented influence on bone metabolism during the previous 12 months, including treatment with antiresorptive or anabolic compounds for osteoporosis.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Collection of blood serum for molecular and biochemical tests
Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
Compilation of questionnaires (AcroQol, SF-36)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06344650